Topical administration of adrenergic receptor pharmaceutics and nerve growth factor
Author(s) -
Steinle
Publication year - 2010
Publication title -
clinical ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 56
eISSN - 1177-5483
pISSN - 1177-5467
DOI - 10.2147/opth.s10992
Subject(s) - medicine , nerve growth factor , glaucoma , diabetic retinopathy , receptor , pharmacology , neuroprotection , pharmaceutics , tropomyosin receptor kinase a , ophthalmology , endocrinology , diabetes mellitus
Topical application of nerve growth factor (NGF) and adrenergic receptor pharmaceutics are currently in use for corneal ulcers and glaucoma. A recent interest in the neuroprotective abilities of NGF has led to a renewed interest in NGF as a therapeutic for retinal and choroidal diseases. NGF can promote cell proliferation through actions of the TrkA receptor or promote apoptosis through receptor p75(NTR). This understanding has led to novel interest in the role of NGF for diseases of the posterior eye. The role of beta-adrenergic receptor agonists and antagonists for treatments of glaucoma, diabetic retinopathy, and their potential mechanisms of action, are still under investigation. This review discusses the current knowledge and applications of topical NGF and adrenergic receptor drugs for ocular disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom